Cingulate Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CING Nasdaq 2834 www.cingulate.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cingulate Inc.

EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement - Dec 5th, 2025 7:30 am
Cingulate price target lowered to $16 from $17 at Roth Capital - Nov 20th, 2025 5:40 am
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - Nov 18th, 2025 2:27 pm
CING: Third Quarter Results - Nov 17th, 2025 10:04 am
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 6:00 am
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 - Nov 10th, 2025 6:00 am
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control - Oct 28th, 2025 6:00 am
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting - Oct 23rd, 2025 2:45 pm
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date - Oct 14th, 2025 6:00 am
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment - Sep 17th, 2025 6:45 am
CING: NDA Submitted - Aug 25th, 2025 4:55 am
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25 - Aug 21st, 2025 2:35 pm
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights - Aug 19th, 2025 6:45 am
Cingulate Provides Management Team Update - Aug 15th, 2025 7:00 am
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 - Aug 6th, 2025 6:45 am
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 - Jul 29th, 2025 6:00 am
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application - Jul 9th, 2025 6:00 am
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - Jun 18th, 2025 6:00 am
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - May 20th, 2025 6:00 am
CING: First Quarter 2025 Results - May 15th, 2025 6:27 am